Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms
Orly Leiva, Olivia Liu, Anthony Kanelidis, Stanley Swat, L. Gozdecki, Mark N. Belkin, Jonathan Grinstein, Sara Kalantari, Gene Kim, Jeanne M. DeCara, Ben B. Chung, Anand Patel, Olatoyosi Odenike, Eric H. Yang, Michelle Bloom, Jose Alvarez‐Cardona, Joan How, Gabriela Hobbs
Abstract
Patients with myeloproliferative neoplasms (MPNs) are at increased risk for cardiovascular disease. Although thrombosis is a well-recognized complication, emerging evidence indicates that nonthrombotic conditions, including heart failure (HF) and pulmonary hypertension (PH), are also prevalent and associated with adverse cardiovascular and hematologic outcomes. Clinical and preclinical data suggest a shared pathophysiology linking MPNs to the development and progression of cardiomyopathy, HF, and both precapillary and postcapillary PH. Recent studies further support a bidirectional relationship, in which HF and PH are associated with hematologic progression and vice versa. Elucidating the mechanisms underlying these interactions may uncover novel therapeutic targets and inform clinical management. Here, the authors review the pathophysiology and impact of HF and PH in patients with MPNs.